Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Placebo-controlled, double-blind, parallel group, fixed dose study of KW-6002 (istradefylline) in the treatment of Parkinson's disease (phase 2 study)

Next Previous
X
Search
Trial Profile

Placebo-controlled, double-blind, parallel group, fixed dose study of KW-6002 (istradefylline) in the treatment of Parkinson's disease (phase 2 study)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Istradefylline (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Sponsors Kyowa Hakko Kirin; Kyowa Kirin

    • Most Recent Events

    • 07 Jan 2022 New source identified and integrated (Japan Pharmaceutical Information Center - Clinical Trials Information record: JapicCTI070380).
    • 07 Feb 2017 Kyowa Hakko Kirin Co., Ltd formed in Oct 2008,and study has been completed in Aug 2008,hence not added in association
    • 13 Apr 2010 Primary endpoint 'Off time' has been met, according to an article published in Movement Disorders.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top